The regulatory role of m⁶A methylation modification in metabolic syndrome pathogenesis and progression

Metabolic syndromes are characterized by various complications caused by disrupted glucose and lipid metabolism, which are major factors affecting the health of a population. However, existing diagnostic and treatment strategies have limitations, such as the lack of early diagnostic and therapeutic approaches, variability in patient responses to treatment, and cost-effectiveness. Therefore, developing alternative solutions for metabolic syndromes is crucial. N6-methyladenosine (m⁶A) is one of the most abundant modifications that determine the fate of RNA. m⁶A modifications are closely associated with metabolic syndrome development and present novel prospects for clinical applications. Aberrant m⁶A modifications have been detected during inflammatory infiltration, apoptosis, autophagy, iron sagging, necrosis, and scorching during metabolic syndrome pathogenesis and progression. However, few reviews have systematically described the correlation between m⁶A modifications and these factors concerning metabolic syndrome pathogenesis and progression. This study summarizes the m⁶A methylation regulators and their roles in metabolic syndrome development, highlighting the potential of m⁶A modification as a biomarker in metabolic disorders.